

This article was downloaded by: [Imperial College of London]

On: 17 July 2009

Access details: Access Details: [subscription number 908786156]

Publisher Informa Healthcare

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Prehospital Emergency Care

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title-content=t713698281>

### INTRANASAL ADMINISTRATION OF NALOXONE BY PARAMEDICS

Erik D. Barton <sup>a</sup>; Joseph Ramos <sup>a</sup>; Christopher Colwell <sup>a</sup>; Jeff Benson <sup>a</sup>; Jeff Baily <sup>a</sup>; William Dunn <sup>a</sup>

<sup>a</sup> Division of Emergency Medicine, University of Utah Health Sciences Center (EDB), Salt Lake City, Utah; the Department of Emergency Medicine, Denver Health Medical Center (JR, CC), Denver, Colorado; and the Denver Health Paramedic Division (CC, JB, JB, WD), Denver, Colorado..

Online Publication Date: 01 January 2002

**To cite this Article** Barton, Erik D., Ramos, Joseph, Colwell, Christopher, Benson, Jeff, Baily, Jeff and Dunn, William(2002)'INTRANASAL ADMINISTRATION OF NALOXONE BY PARAMEDICS',*Prehospital Emergency Care*,6:1,54 — 58

**To link to this Article:** DOI: 10.1080/10903120290938797

**URL:** <http://dx.doi.org/10.1080/10903120290938797>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

# INTRANASAL ADMINISTRATION OF NALOXONE BY PARAMEDICS

Erik D. Barton, MD, MS, Joseph Ramos, MD, Christopher Colwell, MD,  
Jeff Benson, EMT-P, Jeff Baily, EMT-P, William Dunn, EMT-P

## ABSTRACT

**Introduction.** Naloxone is a medication that is frequently administered in the field by paramedics for suspected opioid overdoses. Most prehospital protocols, however, require this medication to be given to patients intravenously (IV) or intramuscularly (IM). Unfortunately, intravenous line placement may be problematic and time-consuming in chronic IV drug users. There may also be a delay in patient response to opioid reversal with IM absorption of naloxone. Additionally, routine use of needles in high-risk populations poses an increased risk of occupational blood exposures to paramedics. **Objective.** To prospectively test the effectiveness of intranasal (IN) naloxone administration by paramedics. This preliminary report summarizes the first month's experience in the city of Denver. **Methods.** Naloxone was first administered to patients found unconscious in the field using a nasal mucosal atomizer device (MAD). Patients were then treated using standard prehospital protocols, which included IV line placement and medications, if they did not immediately respond to IN naloxone. Time to patient response was recorded. **Results.** A total of 30 patients received IN naloxone in the field over a one-month period. Of these, 11 patients responded to either IN or IV naloxone. Ten (91%) patients responded to IN naloxone alone, with an average response time of 3.4 minutes. Seven patients (64%) did not require an IV in the field after response to IN naloxone. **Conclusions.** Intranasal naloxone may provide a safe, rapid, effective way to manage suspected opioid overdoses in the field. Use of this route may decrease paramedic exposures to blood-borne diseases. The addition of IN naloxone administration to prehospital protocols should be considered as an initial therapy for suspected opioid abusers. **Key words:** naloxone; opioid; overdose; paramedics; intranasal; drug abuse.

PREHOSPITAL EMERGENCY CARE 2002;6:54-58

Received April 24, 2001, from the Division of Emergency Medicine, University of Utah Health Sciences Center (EDB), Salt Lake City, Utah; the Department of Emergency Medicine, Denver Health Medical Center (JR, CC), Denver, Colorado; and the Denver Health Paramedic Division (CC, JB, JB, WD), Denver, Colorado. Revision received August 27, 2001; accepted for publication August 31, 2001.

Presented at the First Mediterranean Emergency Medicine Congress, Stresa, Italy, September 2001; and the American College of Emergency Physicians Scientific Assembly Research Forum, Chicago, Illinois, October 2001.

Supported with Muscosal Atomizer Devices (MAD) supplied by Wolfe-Tory Medical, Inc., Salt Lake City, UT.

Address correspondence and reprint requests to: Erik D. Barton, MD, MS, University of Utah Health Sciences Center, Division of Emergency Medicine, 1150 Moran Building, 175 North Medical Drive East, Salt Lake City, UT 84132. e-mail: <edbarton@worldnet.att.net>.

When confronted with a patient suffering from a suspected opioid overdose, the drug of choice is naloxone (Narcan) given by intravenous (IV) or intramuscular (IM) route. Unfortunately, opioid addicts who inject drugs can often have limited peripheral venous access. Valuable time may be lost in trying to gain IV access if multiple attempts are required. Although the IM and subcutaneous (SQ) routes have been shown to be effective, they have a much slower rate of absorption and typically require a much longer time period for the patient to respond.<sup>1,2</sup> Additionally, emergency medical services (EMS) personnel are at risk for inadvertent needlesticks when attempting to place IV lines or give IM or SQ injections in the field. These patients typically pose an increased risk of blood-borne diseases such as hepatitis B, hepatitis C, and HIV.

Other routes of naloxone administration such as sublingual, intralingual, and submental injections also require the use of needles and have shown a delayed onset of action.<sup>3-5</sup> Endotracheal administration of naloxone<sup>6,7</sup> requires placement of an endotracheal tube, and nebulized naloxone is ineffective in reversing opioid effect.<sup>8</sup>

Intranasal (IN) absorption of naloxone has been shown to be almost as rapid as the IV route with sim-



FIGURE 1. The mucosal atomizer device (MAD) attached to a syringe showing the spray pattern of medication.

ilar bioavailability in both animal and human models.<sup>9-11</sup> We are not aware, however, of any published data on the effectiveness of IN naloxone in opioid overdoses often observed in patients such as heroin addicts. Since EMS personnel encounter the majority of these patients in the field, we sought to evaluate the effectiveness of IN naloxone in a prospective prehospital study. This report summarizes our first month's experience.

## METHODS

### Design

This study was performed by the Denver Health Paramedic Division as a prospective evaluation of IN naloxone in all patients who presented with altered mental status (AMS), as "found down" (FD), or with suspected opioid overdose (OD). These patients would otherwise have an IV placed and receive IV naloxone (1–2 mg) by protocol. The preliminary study was performed from February 1 to February 28, 2001, as part of a Paramedic Division Quality Assurance Evaluation of IN naloxone. Institutional review board (IRB) approval was granted.

### Procedure

Patients encountered by paramedics with AMS, FD, or OD were initially administered 2 mg of naloxone IN using a disposable Mucosal Atomizer Device (MAD; Wolfe-Tory Medical, Inc., Salt Lake City, UT) and syringe (Fig. 1). The IN naloxone dose was chosen because 2 mg is the initial IV dose mandated by the Denver Health Paramedic Protocol and bioavailabilities appears to be similar by the two routes.<sup>9-11</sup> One milliliter of the 1-mg/mL solution was administered into each nares, for a total volume of 2 mL (Fig. 2). Paramedics were then instructed to continue to treat all patients as per standard protocols, including airway management, IV line placement, and medications, unless the patient responded and no further treatment was required. If a patient did not respond to IN naloxone within an appropriate time to establish an IV and an airway if necessary, then an IV dose of 2 mg was administered. Times were recorded to the hour and minute on a study sheet (Fig. 3) by paramedic providers and included: time of initial patient encounter, IN naloxone administration, IV insertion, IV naloxone administration, and patient response. Additionally, paramedics were asked to report any obvious abnormalities noted in the patient's nasal mucosa (such as bleeding, deformity, mucus) at the time of IN drug administration.

### Outcomes

The rate of patient response to IN naloxone, defined as a significant improvement in level of consciousness as



FIGURE 2. The mucosal atomizer device (MAD) being used for intranasal administration of naloxone on a patient (paramedic volunteer).

determined by paramedics, prior to IV insertion or to IV administration of a second dose of naloxone was measured. Additionally, the time of response to naloxone was measured.

## RESULTS

During the study period a total of 30 patients received IN naloxone using the MAD. A total of 13 patients (43%) responded to either naloxone by any route ( $n = 11$ ) or dextrose ( $n = 2$ ) given by paramedics in the field. There were 11 patients with AMS listed as the indication for naloxone administration, seven patients with FD listed, and 12 patients with suspected OD listed. Of these, one patient responded to naloxone in the AMS group (9%), no patients responded in the FD group (0%), and ten patients responded in the OD group (83%).

Of the 11 naloxone responders there were ten patients (91%) who responded to IN naloxone alone. The average time of response was 3.4 minutes (range 2 to 6 minutes). One patient responded to IV naloxone and not to IN naloxone alone. Appropriate response occurred at 11 minutes after IN administration and the patient was noted to have a significant amount of epistaxis. Seven of the 11 naloxone responders (64%) did not require IV placement in the field.

## DISCUSSION

The use of IN drug administration has long been considered an alternative route for a wide variety of medications. More importantly, IN administration of several medications used in the prehospital setting (atropine, dextrose, diazepam, epinephrine, glucagon, lidocaine, midazolam, morphine, naloxone, and nitroglycerine (Table 1) has been studied to assess the effectiveness of this route of therapy.<sup>11-20</sup> While effective in many circumstances, however, the IN route has yet to

## PREHOSPITAL INTRANASAL NARCAN

(For Quality Assurance/Performance Improvement Purposes Only)

### PROTOCOL FOR DEVICE USE:

- 1) Time of first contact noted as accurately as possible.
- 2) Load syringe with 2 mg of Narcan and nasal atomizer.
- 3) Administer intranasal Narcan via rapid intranasal mist spray of 1cc to each nostril.
- 4) Time of administration accurately noted and whether patient responded.
- 5) Continue normal attempt(s) to gain IV access and secure airway as needed.
- 6) Record time of IV Narcan if given and whether patient responded.

**NOTE: Protocol stops after patient response.**

### PATIENT DATA:

DATE: \_\_\_\_\_ TRIP #: \_\_\_\_\_

INDICATION for Narcan: Opioid overdose    Altered mental status    Found down

Other: \_\_\_\_\_

- 1) TIME OF FIRST PATIENT CONTACT: \_\_\_\_\_
- 2) TIME INTRANASAL NARCAN ADMINISTERED: \_\_\_\_\_
- 3) TIME IV LINE STARTED: \_\_\_\_\_
- 4) DID THE PATIENT AROUSE AFTER INTRANASAL NARCAN:    Yes    No  
(If No, then continue with Intravenous Narcan)
- 5) TIME IV NARCAN GIVEN: \_\_\_\_\_ RESPONSE:    Yes    No
- 6) RESPONSE TO OTHER MEDICATION:    Yes (med) \_\_\_\_\_    No
- 7) TIME OF PATIENT RESPONSE: \_\_\_\_\_

NASAL abnormalities noted: Septal abnormality    Epistaxis    Mucous  
Trauma    Other: \_\_\_\_\_

COMPLICATIONS/COMMENTS: \_\_\_\_\_

**\*\*\* NOTE \*\*\* PLEASE ATTACH COMPLETED FORM TO TRIP SHEET**

FIGURE 3. The paramedic recording sheet for the prehospital intranasal naloxone study.

replace standard IV therapy in the vast majority of prehospital treatment protocols.

The risk of occupational blood exposure to prehospital providers has been demonstrated to increase with more years of service. In fact, a risk as high as 25 blood contacts per 1,000 EMS calls has been reported in the literature.<sup>21</sup> While only about 2–5% of these are needlestick exposures, there is also significant risk with exposures to nonintact skin, mucous membranes, and eyes (from splashes).<sup>22</sup> Routine use of IV lines and medications, especially in nontrauma patients, may account for the majority of these exposures. Similar risks have been observed in the hospital setting, and

the response over the past several years has been to develop safer needle disposal systems as well as needle-less drug delivery IV lines. Unfortunately, these systems are unavailable or cumbersome to use in the prehospital setting. Consequently, the risk of paramedic needle exposures to blood-borne infectious diseases continues to pose a significant threat.

Naloxone has been found to have almost 100% bioavailability through the nasal mucosa in animal models and in human opioid addicts.<sup>9–11</sup> Subsequently, IN naloxone has an onset of action and plasma level that make it indistinguishable from IV naloxone.<sup>9</sup> Though accepted as an alternative route of

administration, no studies have been previously reported using IN naloxone as an initial mode of treatment in overdose patients. We chose a staged protocol using the IN route first, followed by an IV dose if necessary. This was done to determine both the rate of response within a limited time period and the number of IV attempts that could be avoided in the field if the patient responded appropriately. Issues such as informed consent and blinded treatment protocols would be more difficult to perform in the prehospital setting for an appropriate comparison study.

This study attempts to address the efficacy of IN naloxone by rapidly administering the IN drug upon initial patient evaluation. Standard prehospital treatment protocols were subsequently followed. The purpose of such a protocol was to assess the rate of response of patients given IN naloxone relative to subsequent IV line placement and need for repeat doses of IV medication. The results demonstrate a 91% response rate to the IN naloxone for all patients who responded to naloxone. This result strongly suggests that the IN route could be used successfully in a majority of patients to speed reversal of opioid intoxication. With rapid administration and easy access to the nasal mucosa, the IN route may, in fact, reduce the duration of respiratory depression and decrease the number of prehospital intubations often seen in this patient population. Additionally, a significant number of patients in this study (64%) did not require IV placement in the field, which may be a safer practice when treating opioid abusers outside of the emergency department.

The one patient in our series who did not respond to IN naloxone and subsequently responded to IV naloxone was noted to have epistaxis. Physical factors such as nasal septum abnormalities, trauma, epistaxis, excessive mucus, and mucosal destruction from other intranasal drug use (i.e., cocaine) may have a significant effect on the rate and amount of absorption of IN medications. Drug abusers might be a population at higher risk for these nasal abnormalities for a variety of reasons. Additionally, paramedics should continue to use blood exposure precautions for external sources of bleeding, such as epistaxis, in these patients. Prospective evaluation of the nares to assess for any abnormalities may be required prior to the administration of IN naloxone. Further study will most likely elucidate what percentage of these patients will continue to require IV naloxone.

## CONCLUSION

Intranasal naloxone has been demonstrated to be a very easy route for drug administration in the field with a high patient response rate in this preliminary study. This method utilizes an inexpensive device that provides rapid administration of the medication with

TABLE 1. Intranasal Medications Previously Studied\* for Systemic Indications

| Indication          | Medications   |
|---------------------|---|
| Analgesia           | Fentanyl <sup>23</sup><br>Sufentanil <sup>24</sup><br>Buprenorphine <sup>25</sup>   |
| Antiemetics         | Meclizine <sup>26</sup><br>Metoclopramide <sup>27</sup>   |
| Antihypertensives   | Angiotensin II <sup>28</sup><br>Hydralazine <sup>29</sup><br>Nifedipine <sup>30</sup><br>Nitroglycerine <sup>31</sup><br>Propranolol <sup>32</sup><br>Verapamil <sup>33</sup> |
| Cardiac arrest/ACLS | Atropine <sup>34</sup><br>Epinephrine <sup>35</sup><br>Lidocaine <sup>36</sup>  |
| Drug overdose       | Naloxone <sup>10</sup>  |
| Headache therapy    | Butorphanol <sup>37</sup><br>Dihydroergotamine <sup>38</sup><br>Lidocaine <sup>39</sup><br>Sumatriptan <sup>40</sup>  |
| Hypoglycemia        | Dextrose <sup>41</sup><br>Glucagon <sup>42</sup>  |
| Sedation            | Diazepam <sup>43</sup><br>Ketamine <sup>44</sup><br>Midazolam <sup>45</sup>   |
| Seizures            | Diazepam <sup>46</sup><br>Midazolam <sup>47</sup>   |
| Miscellaneous       | Gentamycin <sup>48</sup><br>Neostigmine <sup>49</sup>   |

\*For complete reference citations, see the reference list. ACLS = Advanced Cardiac Life Support.

minimal risk of blood-borne exposure. Use of an IN naloxone protocol may promote a safer practice for paramedics while maintaining effective treatment for patients with opioid overdoses.

## References

- Wanger K, Brough L, Macmillan I, Goulding J, MacPhail I, Christenson JM. Intravenous vs. subcutaneous naloxone for out-of-hospital management of presumed opioid overdose. *Acad Emerg Med.* 1998;5:293-9.
- Sporer KA, Firestone J, Issacs SM. The prehospital treatment of heroin overdoses. *Acad Emerg Med.* 1996;3:360-7.
- Maio RF, Gaukel B, Freeman B. Intralingual naloxone injection for narcotic-induced respiratory depression. *Ann Emerg Med.* 1987;16:572-3.
- Salvucci AA, Eckstein M, Iscovich AL. Submental injection of naloxone. *Ann Emerg Med.* 1995;25:719-20.
- Preston KL, Bigelow GE, Liebson IA. Effects of sublingually given naloxone in opioid-dependent human volunteers. *Drug Alcohol Depend.* 1990;25:27-34.
- Tandberg D, Abercrombie D. Treatment of heroin overdose with endotracheal naloxone. *Ann Emerg Med.* 1982;11:443-5.
- Greenberg MI, Roberts JR, Baskin SI. Endotracheal naloxone for reversal of morphine-induced respiratory depression in rabbits. *Ann Emerg Med.* 1980;9:289-92.
- Karras DJ, Levy DB, Domingo L. Nebulized naloxone for reversal of narcotic intoxication: results of a pilot trial [abstract]. *Ann Emerg Med.* 1998;32:S56.

9. Hussain A, Kimura R, Huang CH. Nasal absorption of naloxone and buprenorphine in rats. *Int J Pharm.* 1984;21:233-7.
10. Loimer N, Hofman P, Chaundry HR. Nasal administration of naloxone is as effective as the intravenous route in opiate addicts. *Int J Addict.* 1994;29:819-27.
11. Loimer N, Hofman P, Chaundry HR. Nasal administration of naloxone for detection of opiate dependence. *J Psychiatr Res.* 1992;26:39-43.
12. Laurikainen E, Koulu M, Kaila T, Scheinin M, Isalo E. Evaluation of the systemic anticholinergic activity of nasally administered ipratropium bromide. *Rhinology.* 1988;26:133-8.
13. Breuniger H, Feine U. [On the uptake of labeled glucose by the mucose membranes of the nose, mouth, and middle ear]. *Arch Klin Exp Ohren Nasen Kehlkopfheilkd.* 1968;194:440-2.
14. Platt SR, Randell SC, Scott KC, Chrisman CL, Hill RC, Gronwall RR. Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs. *Am J Vet Res.* 2000;61:651-4.
15. Bleske BE, Rice TL, Warren EW, et al. Effect of dose on the nasal absorption of epinephrine during cardiopulmonary resuscitation. *Am J Emerg Med.* 1996;14:133-8.
16. Pontiroli AE. Peptide hormones: review of current and emerging uses by nasal delivery. *Adv Drug Deliv Rev.* 1998;29:81-7.
17. Scavone JM, Greenblatt DJ, Fraser DG. The bioavailability of intranasal lignocaine. *Br J Clin Pharmacol.* 1989;28:722-4.
18. Scheepers M, Scheepers B, Clarke M, Comish S, Ibitoye M. Is intranasal midazolam an effective rescue medication in adolescents and adults with severe epilepsy? *Seizure.* 2000;9:417-22.
19. Ugwoke MI, Exaud S, Van Der Moot G, Verbeke N, Kinget R. Bioavailability of apomorphine following intranasal administration of mucoadhesive drug delivery systems in rabbits. *Eur J Pharm Sci.* 1999;9:213-9.
20. Grover VK, Sharma S, Mahajan RP, Singh H. Intranasal nitroglycerine attenuates pressor response to tracheal intubation in beta-blocker treated hypertensive patients. *Anaesthesia.* 1987;42:884-7.
21. Marcus R, Srivastava PU, Bell DM, et al. Occupational blood contact among prehospital providers. *Ann Emerg Med.* 1995;25:776-9.
22. Reed E, Daya MR, Jui J, Grellman K, Gerber L, Loveless MO. Occupational infections disease exposures in EMS personnel. *J Emerg Med.* 1993;11:9-16.
23. Ralley FE. Intranasal opiates: old route for new drugs. *Can J Anaesth.* 1989; 36: 491-3.
24. Henderson JM, Brodsky DA, Fisher DM, Brett CM, Hertzka RE. Pre-induction of anesthesia in pediatric patients with nasally administered sufentanil. *Anesthesiology.* 1988;68:671-5.
25. Eriksen J, Jensen NH, Kamp-Jensen M, et al. The systemic availability of buprenorphine administered by nasal spray. *J Pharm Pharmacol.* 1989;41:803-5.
26. Chovan JP, Klett RP, Rakiety N. Comparison of meclizine levels in the plasma of rats and dogs after intranasal, intravenous, and oral administration. *J Pharm Sci.* 1985;74:1111-3.
27. Scaglione F, Scanni A, Tomirotti M, et al. Pharmacokinetics and bioavailability of metoclopramide nasal spray versus metoclopramide intravenous in healthy volunteers and cancer patients [English]. *Arzneimittelforschung.* 1993;43:986-8.
28. Derad I, Willeke K, Pietrowsky R, et al. Intranasal angiotensin II directly influences central nervous regulation of blood pressure. *Am J Hypertens.* 1998;11:971-7.
29. Landau AJ, Eberhardt RT, Frishman WH. Intranasal delivery of cardiovascular agents: an innovative approach to cardiovascular pharmacotherapy. *Am Heart J.* 1994;127:1594-9.
30. Iyer VS, Russell WJ. Nifedipine for postoperative blood pressure control following coronary artery vein grafts. *Ann R Coll Surg Engl.* 1986;68:73-5.
31. Grover VK, Sharma S, Mahajan RP, Singh H. Intranasal nitroglycerine attenuates pressor response to tracheal intubation in beta-blocker treated hypertensive patients. *Anaesthesia.* 1987; 42:884-7.
32. Landau AJ, Frishman WH, Alturk N, et al. Improvement in exercise tolerance and immediate beta-adrenergic blockade with intranasal propranolol in patients with angina pectoris. *Am J Cardiol.* 1993;72:995-8.
33. Arnold TH, Tackett RL, Vallner JJ. Pharmacodynamics of acute intranasal administration of verapamil: comparison with i.v. and oral administration. *Biopharm Drug Dispos.* 1985;6:447-54.
34. Laurikainen E, Koulu M. Evaluation of the systemic anticholinergic activity of nasally administered ipratropium bromide. *Rhinology.* 1988;26:133-8.
35. Bleske BE, Warren EW, Rice TL, et al. Comparison of intravenous and intranasal administration of epinephrine during CPR in a canine model. *Ann Emerg Med.* 1992;21:1125-30.
36. Scavone JM, Greenblatt DJ. The bioavailability of intranasal lignocaine. *Br J Clin Pharmacol.* 1989;28:722-4.
37. Melanson SW, Morse JW, Pronchik DJ, Heller MB. Transnasal butorphanol in the emergency department management of migraine headache. *Am J Emerg Med.* 1997;15:57-61.
38. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. *Neurology.* 1994;44: 447-53.
39. Kudrow L, Kudrow DB, Sandweiss JH. Rapid and sustained relief of migraine attacks with intranasal lidocaine: preliminary findings. *Headache.* 1995;35:79-82.
40. Moore KH, Hussey EK, Shaw S, et al. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. *Cephalalgia.* 1997;17:541-50.
41. Breuninger H, Feine U. [Different absorption of radioactively labeled glucose by human nasal mucosa with acid and alkaline pH values]. *Arch Klin Exp Ohren Nasen Kehlkopfheilkd.* 1969;194:440-2.
42. Hvidberg A, Djurup R, Hilsted J. Glucose recovery after intranasal glucagon during hypoglycaemia in man. *Eur J Clin Pharmacol.* 1994;46:15-7.
43. Bechgaard E, Gizurason S, Hjortkjaer RK. Pharmacokinetic and pharmacodynamic response after intranasal administration of diazepam to rabbits. *J Pharm Pharmacol.* 1997;49:747-50.
44. Malinovsky JM, Servin F, Cozian A, et al. Ketamine and norke-tamine plasma concentrations after i.v., nasal and rectal administration in children. *Br J Anaesth.* 1996;77:203-7.
45. Bjorkman S, Rigemar G, Idvall J. Pharmacokinetics of midazolam given as an intranasal spray to adult surgical patients. *Br J Anaesth.* 1997;79:575-80.
46. Gizurason S, Gudbrandsson FK. Intranasal administration of diazepam aiming at the treatment of acute seizures: clinical trials in healthy volunteers. *Biol Pharm Bull.* 1999;22:425-7.
47. Kendall JL, Reynolds M, Goldberg R. Intranasal midazolam in patients with status epilepticus. *Ann Emerg Med.* 1997;29:415-7.
48. Wang JQ, Bu GX. An experimental study on nasal absorption of gentamycin in dogs. *Chin Med J Engl.* 1994;107:219-21.
49. Sghirlanzoni A, Pareyson D, Benvenuti C, et al. Efficacy of intranasal administration of neostigmine in myasthenic patients. *J Neurol.* 1992;239:165-9.